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ABSTRACT 
The significance of adipose tissue and obesity has been recognized in numerous pathologies. 
However, the mechanisms behind this connection are not yet completely understood. The 
aim of this thesis was to investigate the roles of Liver X Receptor (LXR), V-maf 
musculoaponeurotic fibrosarcoma oncogene homolog B (MAFB) and Salt-inducible kinases 
(SIKs) in primary human adipocytes with focus on metabolic regulation and inflammation. 
Our overall hypothesis was that these factors may influence metabolism and inflammation 
in human white adipose tissue (WAT). 
In paper I, we studied the effects of LXR activation on human basal lipolysis. 
We show that stimulation of LXR using the LXR agonist GW3965 enhances spontaneous 
lipolysis, measured as glycerol released into culture medium. We demonstrate that 
hormone-sensitive lipase (HSL) and perilipin 1 (PLIN1), two proteins important for lipolysis, 
are downregulated on both mRNA and protein level by GW3965 treatment, which changes 
the morphology of the lipid droplet coating. Using chromatin immunoprecipitation we show 
that LXR binds to the proximal promoters of both LIPE (encoding HSL) and PLIN1. 
Furthermore, we demonstrate that LXRα is the isoform mediating increased lipolysis. PLIN1 
knockdown in combination with GW3965 treatment indicate that PLIN1 downregulation 
was the main mechanism by which LXR activation increase glycerol release in human 
adipocytes. 
In paper II we examined the role of LXR in human adipocyte glucose uptake. 
We identified three proteins important for insulin signalling – AKT2, c-CBL associated protein 
(CBL) and caveolin 1 (CAV1) – to be downregulated by LXR activation. LXR activation reduced 
AKT2 phosphorylation and GLUT4 translocation to the plasma membrane, which resulted in 
reduced insulin-stimulated glucose uptake. In addition, AKT2 and SORBS1 (encoding CAP) 
expression in human WAT was inversely correlating with BMI and severity of insulin 
resistance. We concluded that LXR is an inhibitor of insulin-stimulated glucose uptake in 
human adipocytes, likely via transcriptional suppression of AKT2, SORBS1 and CAV1. 
In paper III, we investigated the role of MAFB in human WAT. MAFB mRNA 
expression was upregulated in obesity and downregulated after weight loss in adipose 
tissue from four different human cohorts. We found that the expression of MAFB is 
increased during adipocyte differentiation and that it mediates effects of TNFα-stimulation 
on lipid accumulation and basal lipolysis. In turn, knockdown of MAFB in adipocytes resulted 
in reduced expression of pro-inflammatory factors. MAFB was differentially regulated in 
response to TNFα treatment in adipocytes (downregulated) vs. monocytes (upregulated). 
MAFB was mainly expressed in adipose tissue macrophages and its expression correlated 
positively with macrophage- and pro-inflammatory markers in WAT, and negatively with 
insulin-stimulated lipogenesis and stimulated lipolysis in human mature adipocytes, 
suggesting that it might be involved in the development of unhealthy glucose- and lipid 
metabolism.  
In paper IV, we aimed to identify the role of SIKs in human obesity and 
adipose tissue. We found that expression of SIK2 and SIK3 mRNA in human WAT was 
downregulated in obesity, upregulated after weight loss and correlated negatively with 
insulin resistance. SIK2 was the most highly expressed SIK isoform in human adipocytes. 
Both basal and insulin-stimulated glucose uptake were inhibited by SIK inhibitor. SIK 
inhibition also lead to reduced phosphorylation of histone deacetylase 4 (HDAC4) and CREB 
regulated transcription coactivator 1 (CRTC2), which may potentially mediate the 
attenuation of glucose uptake. Taken together, SIK2 may have a protective role in obesity-
induced loss of insulin sensitivity. 
  
In summary, we have identified the roles of three factors in human 
adipocytes, all of which were previously uncharacterised in human WAT. We show that LXR 
enhances spontaneous lipolysis while inhibiting insulin-stimulated glucose uptake in human 
adipocytes, two features associated with an unfavourable metabolic profile. We also found 
that MAFB and SIK2 expression is regulated by obesity and inflammation. Finally, we 
demonstrate that MAFB is itself a regulator of inflammation in human adipocytes and that 
SIK2 positively regulates glucose uptake in human adipocytes. Our findings contribute to the 
understanding of the metabolic syndrome and its development in obesity.  
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1 BACKGROUND 
 
1.1 OBESITY 
As obesity is growing into an epidemic worldwide [1], an endless number of diseases follow 
in its path. Obesity does not only cause serious metabolic disturbances such as type 2 
diabetes and fatty liver but is also associated with higher rates of co-morbidities such as 
chronic low-grade inflammation, atherosclerosis, hypertension, asthma, cancer, depression, 
Alzheimer’s disease, infertility, birth complications, sleep apnoea, premature aging and 
impaired physical ability. The grounds for this epidemic are numerous and include a 
sedentary lifestyle and overnutrition, but also less obvious causes such as sleep deprivation, 
fat-promoting viruses, an obesogenic gut flora springing from excessive hygiene and/or 
unhealthy foods, effective indoor temperature regulation, around-the-clock feeding, toxins 
(e.g. bisphenol), stress, anxiety, and the availability of highly palatable foods which disrupt 
the satiety system [2-7]. Three well-known methods of weight reduction are diet, exercise 
and bariatric surgery. However, they all have their limitations. Classical calorie-reducing 
dieting and exercise seldom produce long-lasting results and demand immense willpower 
from affected individuals. Bariatric surgery is mainly available to individuals with morbid 
obesity, and comes with the risk of side-effects and complications such as nutritional 
malabsorption, dumping syndrome, and reflux [8]. Obesity is characterised by an excess of 
adipose tissue and the level of obesity is defined by body mass index (BMI) which is 
calculated by dividing an individual’s weight in kilograms by their squared height in 
centimetres. The BMI scale is divided into categories listed in table 1.  
 
Table 1. Definition of BMI classes 
BMI class BMI (kg/m2) 
Underweight <18.5 
Normal weight 18.5-24.9 
Overweight 25.0-29.9 
Obese >30 
Morbidly obese >40 
 
Some of the medical treatments widely used today in the management of obesity-related 
health issues target insulin resistance and glucose intolerance. These treatments – such as 
insulin injections, metformin and, more rarely, thiazolidinediones – come with a range of 
side-effects, including weight gain, osteoporosis or intestinal distress [9]. Although lifestyle 
change can have great impact on the weight of some individuals, there will always be a 
category where diet and exercise will not be an attractive or possible alternative. This 
category includes persons with severe depression and those with physical disabilities or 
additional diseases that complicate exercise ability. Therefore, there is a need for further 
characterisation of adipose tissue and for the development of safe and effective drugs to 
treat both obesity itself and its secondary ailments.  
 
1.2 WHITE ADIPOSE TISSUE 
White adipose tissue (WAT) is what most of us have in mind when we think about body fat. 
Brown adipose tissue, which is located in different areas, largely possesses distinct 
properties from WAT and will not be addressed in this thesis. WAT develops at numerous 
locations throughout the body and have many different functions such as energy storage 
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and maintaining energy homeostasis, insulation and hormonal signalling. WAT is not only 
located in visual depots such as legs, belly, arms and breasts but also in the foot soles, bone 
marrow, eye, and surrounding the heart and other inner organs. There are two major 
divisions of WAT; subcutaneous WAT which is located peripherally beneath the skin, and 
visceral WAT which is embedded among the internal organs. Visceral WAT is more 
metabolically active than subcutaneous WAT in that it exhibits a higher flux of fatty acids 
(FAs) which is released directly into the portal circulation and to the liver. Visceral WAT is 
also considered more prone to inflammation. [10] WAT is a complex organ of great 
heterogeneity and consists of a number of cell types described below. When the term 
adipose tissue is used in this thesis, it refers to subcutaneous WAT containing all cell types. 
 
1.2.1 Adipocytes 
Adipocytes are one of the body’s largest cell types and make up 20-40% of the total cell 
number in adipose tissue, but over 90% of the tissue volume. The renewal rate for 
adipocytes in humans is about 10% per year [11]. Their main function is to store energy in 
the form of lipids and they largely consist of a large lipid droplet which constitutes about 
90% of the cell mass. A narrow cytoplasm surrounds the lipid droplet and the nucleus is 
located near the plasma membrane [12]. The functions of the adipocyte are described in 
detail in chapter 1.3. 
 
1.2.2 Adipocyte precursor cells 
Adipocyte progenitor cells are found in the stromal vascular fraction (SVF) and include 
mesenchymal stem cells and pre-adipocytes.  Mesenchymal stem cells in adipose tissue 
have the ability to differentiate into chondrocytes, osteocytes, myocytes and adipocytes. 
Pre-adipocytes are small adipocyte-precursor cells destined to develop into adipocytes in 
vivo. Pre-adipocytes display distinct gene expression profiles depending on their depot of 
origin, which they retain after isolation and in vitro differentiation [13]. A complex 
transcriptional network is activated in the adipogenic process. This network includes the 
master regulator of adipogenesis peroxisome proliferator-activated receptor gamma 
(PPARγ), CCAAT/enhancer-binding proteins (CEBPs) and sterol regulatory element-binding 
protein-1c (SREBP-1c) [14]. 
 
1.2.3 Macrophages 
Macrophages develop from monocytes and their main function is to eliminate cells affected 
by infection through either phagocytosis or by cytokines [15]). Macrophages are a natural 
and necessary component of adipose tissue. They proliferate in adipose tissue during 
periods of increased lipolysis, such as weight loss and fasting, in order to take care of an 
excess of released FAs [16-18]. They also take up FAs released from apoptotic adipocytes, 
protecting the surroundings from lipotoxic effects (further described in section 1.3.3) [19]. 
When adipose tissue expands, adipocytes and macrophages which are already present start 
to secrete proteins promoting macrophage proliferation [18] (see section 1.4.2). The 
macrophages also go through an identity switch from M2 (anti-inflammatory) to M1 (pro-
inflammatory). M1 macrophages initiate secretion of elevated amounts of pro-inflammatory 
cytokines which leads to impaired insulin sensitivity both locally and systemically [20]. 
However, the M1/M2 division is increasingly considered as an oversimplification. 
 
1.2.4 Additional adipose tissue cell types 
Adipose tissue also contains endothelial cells, lymphoid cells, mast cells, fibroblasts and 
leukocytes. These cell types will not be addressed in this thesis. 
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1.3 FUNCTIONS OF THE ADIPOCYTE 
The main functions of the adipocyte is energy storage after feeding and in times of 
abundance, and energy release between meals and in times of food shortage. Storage and 
release are operated by lipogenesis and lipolysis, respectively. Insulin plays a crucial part in 
the regulation of these processes. 
 
1.3.1 Adipocytes as targets of insulin signalling 
Insulin is a peptide released from pancreatic beta cells in the islets of Langerhans in 
response to elevated post-prandial blood glucose levels. Many cell types respond to insulin 
signalling, including adipocytes. In adipocyte biology, insulin is one of the most important 
hormones, controlling differentiation, growth and energy homeostasis. Insulin is strongly 
pro-adipogenic and energy homeostasis is controlled by insulin through regulation of 
lipogenesis, FA uptake and lipolysis.  
 
The control of glucose homeostasis by insulin is a tightly regulated process, and when 
dysregulated or completely lacking (such as in type 1 diabetes) it poses immediate and long-
term danger. Malfunctioning insulin signalling leads to insulin resistance, which is described 
in section 1.5.  
 
The immediate effect of an activated insulin signalling cascade is glucose uptake, where the 
ultimate target is translocation of the glucose transporter protein GLUT4 from intracellular 
stores to the plasma membrane. GLUT4 translocation and recycling is a complex process 
which involves as many as 70 proteins and a number of phosphorylation events. Two insulin 
signalling pathways have been described; the phosphatidylinositol-3 kinase (PI3K)-
dependent pathway and the non-canonical CBL-TC10 pathway. The pathways are depicted 
in Fig. 1. Both cascades are initiated when insulin binds extracellularly to the insulin receptor 
with subsequent tyrosine auto-phosphorylation of the intracellular parts of the receptor.  
 
In the PI3K pathway, this attracts insulin receptor substrate (IRS) proteins which bind the 
tyrosine phoshorylated residues and are themselves tyrosine phosphorylated. IRS proteins 
serve as docking sites for PI3K which catalyses the conversion of 
phosphatidylinositol-4,5-diphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate 
(PIP3). Phosphoinositide Dependent Protein Kinase 1 (PDPK1) and AKT then dock at PIP3 in 
the plasma membrane. AKT is phosphorylated by PDK1 at Thr308 and by mammalian target 
of rapamycin complex 2 (mTORC2) at Ser473 [21, 22]. AKT is thereby fully activated and 
catalyses an inhibitory phosphorylation of the RAB GAP Akt substrate of 160 kDa (AS160). By 
inactivating AS160, GLUT4-containing vesicles are released from their intracellular 
sequesterisation and can translocate to the plasma membrane.  
 
The CBL-TC10 pathway initiates with the binding of APS, CBL and C-cbl associated protein 
(CAP) to the insulin receptor. CBL is phosphorylated by the receptor which stimulates the 
binding of CRK and the guanine nucleotide exchange factor C3G to the plasma membrane. 
The small GTPase TC10 is activated by C3G and facilitates the translocation of GLUT4 to the 
PM. [23-25]. The importance of the CBL-TC10 pathway has, however, been questioned [26]. 
An array of proteins are involved in the final stages of translocation and recycling of GLUT4 
but will not be further described [22]. Basal glucose uptake is, independently of insulin 
signalling, mediated by the ubiquitously expressed glucose transporter GLUT1.  
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Fig.1. CBL-TC10- and PI3K –dependent insulin signalling pathways. Source: Leto & Saltiel, Nature Reviews. 
Molecular Cell Biology [22]. Printed with permission from the publisher. 
 
AKT has been described as a central hub, with a key role in insulin signalling. There are three 
isoforms of AKT; AKT1, -2 and 3. AKT2 is the major isoform important for glucose uptake. 
AKT1 has primarily been implicated in cellular growth and anti-apoptosis but may have a 
compensatory role in glucose uptake in case of loss of AKT2. AKT3 is important for neuronal 
development. [21]. AKT2 has been repeatedly shown to be crucial for glucose uptake. In 
contrast, one study suggests that AKT2 is de facto expressed in abundance and that minor 
alterations in AKT2 expression does not affect glucose uptake [27]. Of the IRS isoforms IRS1 
and -2, IRS1 has been shown to be the major isoform mediating glucose uptake in 
adipocytes [28]. 
 
In addition to the signalling cascades caveolin 1 (CAV1) has been found to be important for 
insulin effects in adipose tissue [29]. CAV1 is a building block of caveolae located in the PM 
where it regulates insulin-signalling [30] and acts in a stabilising manner on the insulin 
receptor and GLUT4 by preventing their degradation [31].  
 
It is important to mention that only about 10% of insulin-stimulated glucose uptake occurs 
in adipose tissue, while the major target tissue is skeletal muscle [32]. However, insulin 
sensitivity in adipose tissue is vital for systemic metabolic homeostasis [33-35]. 
 
1.3.2 Lipogenesis 
Energy is stored in adipocytes in the form of triglycerides (TGs) in the lipid droplet. Two 
pathways contribute to TG synthesis, a process also known as lipogenesis. The major 
pathway in adipocytes involves the uptake of TGs in the form of FAs from blood. Besides 
promoting glucose uptake, insulin also powerfully stimulates FA uptake. Thus, although FAs 
from the diet are the greatest contributor to lipogenesis and fat tissue growth, this process 
is heavily dependent on insulin, which is released mainly in response to carbohydrate intake. 
TGs in blood are transported in chylomicrons or very low density lipoprotein (VLDL). 
Lipoprotein lipase (LPL) hydrolyses the TGs into FAs which adipocytes are able to take up. 
The expression and activity of LPL is also positively regulated by insulin. The FAs enter the 
adipocytes through the FA transporter FAT/CD36 or passive diffusion. FAs are then subject 
to re-esterification, forming TGs intracellularly, which in turn are joined to the lipid droplet. 
In this pathway, glucose is used for synthesis of glycerol – the TG backbone. [36]  
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The second pathway is denoted de novo lipogenesis (DNL) and involves synthesis of TGs 
from glucose via acetyl-CoA. This process is not very pronounced in adipocytes and does not 
largely contribute to energy storage, and is generally considered to be more important in 
liver, especially in the development of non-alcoholic fatty liver disease. However, DNL in 
adipose tissue may serve as means of producing lipid signalling molecules [37, 38]. 
Unexpectedly, adipocyte DNL takes place in situations of caloric restriction rather than after 
excess energy intake. Adipose tissue DNL was also reported to exert positive effects on 
glucose homeostasis.  [39] Fatty acid synthase, (FAS), acetyl CoA carboxylase (ACC) and 
stearoyl-CoA desaturase (SCD) are important enzymes in the DNL pathway. These enzymes 
are transcriptionally regulated by the lipogenic transcription factors SREBP-1c and 
carbohydrate-response-element-binding protein (ChREBP), of which the latter is more 
important in adipocytes. [38] 
 
1.3.3 Lipolysis 
Energy is mobilised from adipocytes and released in the form of FAs to be utilised mainly by 
muscle. This process is denoted lipolysis, a name derived from the hydrolysis of TGs from 
the lipid droplet. TGs are hydrolysed from the lipid droplet by three enzymes situated on its 
surface but the process is also regulated by a number of non-enzymatic factors. TGs are 
converted into diacylglycerol (DG) via adipose triglyceride lipase (ATGL) and hormone-
sensitive lipase (HSL). DGs are hydrolysed into monoacylglycerol (MG) by HSL and the final 
FA is liberated by monoacylglycerol lipase (MGL). The FAs then either travel bound to 
albumin to its target tissues or can be re-esterified. In addition, one glycerol molecule is 
released per original TG and is transported out of the adipocyte as adipocytes do not 
express the enzyme necessary for phosphorylation of glycerol which is needed for formation 
of the glycerol backbone in the making of triglycerides. [40, 41] 
Basal lipolysis occurs continuously at low rates in adipocytes. Lipolysis can also be triggered 
by hormones. In detail, stimulated lipolysis is initiated with the binding of pro-lipolytic 
factors to their respective receptors. The most physiologically relevant ones are the 
catecholamines adrenaline and noradrenaline which bind to the adrenergic receptors. The 
adrenergic lipolytic pathway is illustrated in Fig. 2. Other factors are also known to stimulate 
lipolysis but will not be addressed here. β adrenergic receptors have a stimulatory effect on 
lipolysis while the α2 adrenergic receptor has an inhibitory effect. The net effect is 
dependent on the relative expression of β versus α2 adrenergic receptors, although β 
adrenergic signalling is normally dominant in human adipocytes [42]. Upon binding by 
catecholamines to the β adrenergic receptors, adenylate cyclase is activated and converts 
ATP into cAMP. cAMP in turn binds and activates protein kinase A (PKA) which 
phosphorylates and activates HSL.  
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Fig. 2. The adrenergic lipolytic pathway in human adipocytes. Source: Lafontan & Langin, Progress in Lipid 
Research [40]. Printed with minor changes and with permission from the publisher. 
 
Besides HSL, ATGL is also regulated hormonally through its cofactor CGI-58. Perilipin 1 
(PLIN1) is a lipid-droplet associated protein which in the unstimulated state physically 
obstructs the lipid droplet from the lipolytic enzymes, thereby blocking lipolysis. In the basal 
state PLIN1 binds CGI-58. When lipolysis is triggered by catecholamines, PLIN1 is 
phosphorylated by PKA upon which CGI-58 is released to activate ATGL and the hydrolysis of 
TGs [43]. PLIN1 also goes through a conformational change itself, which recruits HSL to the 
surface of the lipid droplet [44].  
In obesity, the lipolytic response is often dysregulated; basal lipolysis is increased whereas 
stimulated lipolysis is blunted. Elevated basal lipolysis, or an inability of the adipocyte to 
store lipids, lead to lipid spillover and lipotoxicity. FAs can aggregate ectopically on muscle, 
heart, liver and pancreas, as well as cause internal hepatic fat accumulation. This 
contributes to an impaired ability to clear the blood from glucose, a state termed insulin 
resistance [42] (further described in section 1.5). 
 
1.3.4 The endocrine function of adipocytes 
Adipocytes cross-talk with their close environment and with distant tissues through 
autocrine, paracrine and endocrine processes. This cross-talk is mediated by adipokines; 
peptides secreted from adipocytes. Many adipokines are pro-inflammatory and are 
increasingly expressed as weight gain proceeds (see section 1.4.). These negatively affect 
metabolism, fat distribution, blood pressure and endothelial health. However, not all 
adipokines are of malicious character. For example, leptin is an adipokine almost solely 
expressed by adipocytes. It is of key importance in appetite and energy regulation. Leptin 
travels from adipose tissue to the hypothalamus where it promotes satiety [45]. Along with 
leptin, adiponectin is another highly expressed adipokine with beneficial properties. Its 
expression is decreased in obesity and it has insulin sensitising effects. Adiponectin also 
improves dyslipidemia and inflammation [46]. 
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1.4 INFLAMMATION 
In addition to leptin and adiponectin described above, adipose tissue and adipocytes secrete 
a large number of peptides [47-53]. Three of the most important pro-inflammatory 
adipokines which are also studied in this thesis will be described below. All three are 
regulated by nuclear factor kappa B (NF-κB) as well as expressed and secreted by both 
adipocytes and macrophages [54-56]. 
 
1.4.1 Tumor necrosis factor alpha 
Tumor necrosis factor alpha (TNFα) is an extensively studied cytokine and has been 
connected to a number of pathologies. TNFα works in an auto- and paracrine manner and 
promotes the expression and secretion of other adipokines. TNFα secretion is elevated in 
obesity, correlates negatively with insulin sensitivity [57] and reduces glucose uptake in 
human adipocytes [58]. Its mechanism of action is an inhibition of IR autophosohorylation 
and of IRS1 signalling [57]. TNFα antagonizes PPARγ and thereby inhibits lipid storage and 
glucose uptake by transcriptional regulation. IR, IRS-1 and GLUT4 are examples of genes 
with reduced expression levels as a result of elevated levels of TNFα [59, 60]. Moreover, 
TNFα knockout mice are protected from obesity-induced insulin resistance [61]. A second 
mechanism promoted by TNFα with detrimental effects on health is increased basal 
lipolysis, which leads to augmented FA-levels, in turn also affecting insulin resistance, as 
discussed above. 
 
1.4.2 Monocyte chemoattractant protein 1 
Monocyte chemoattractant protein 1 (MCP-1) is encoded by the CCL2 gene. Similarly to 
TNFα, MCP-1 increases in obesity [62] and is of diabetogenic nature [63]. By paracrine and 
autocrine effects, MCP-1 stimulates macrophage proliferation within adipose tissue. 
Activated macrophages secrete more MCP-1, consolidating a chronic inflammation. [18]. 
 
1.4.3 Interleukin-6 
Interleukin (IL)-6 secreted from adipose tissue has been established in several pathologies of 
obesity, including insulin resistance. Mice receiving acute infusions of IL-6 develop insulin 
resistance without being obese [64]. IL-6 also impairs insulin sensitivity in humans [65] and 
is positively associated with BMI, insulin and occurrence of type 2 diabetes in human 
subjects [66]. 
 
1.5 METABOLIC SYNDROME 
The metabolic syndrome comprises multiple interconnected subconditions such as insulin 
resistance, visceral adipocity, hypertension, dyslipidemia, and high blood pressure. Insulin 
resistance is a major element of the diagnosis. Insulin resistance is characterised by the 
body’s inability to respond properly to insulin and subsequently take up glucose from the 
blood, and precedes type 2 diabetes. High glucose levels are detrimental due to the 
inherent toxicity of glucose. Elevated blood glucose leads to increased reactive oxygen 
species which damage cells and tissues, it glycosylates proteins indiscriminately, thereby 
changing their properties (for example low density lipoprotein), and cause blood vessels 
stiffness. [67] Insulin resistance and insulin sensitivity can be measured by several different 
methods. One method appearing in this thesis is the homeostasis model assessment of 
insulin resistance (HOMA-IR) [68]. The model is based on measurements of fasting plasma 
insulin and glucose in mmol/L and the HOMA-IR index is calculated by the following formula: 
 
  HOMA-IR = 
plasma glucose ∙ plasma insulin
22.5
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In this model, a higher value indicates a higher level of insulin resistance.  
 
Multiple organs are involved in the development of insulin resistance. The condition has 
several possible roots, of which one is a high sugar diet. When sugar intake is high, 
pancreatic beta cells produce high levels of insulin to promote glucose disposal. When 
insulin levels remain high, muscle cells and adipocytes begin to lose their sensitivity to 
insulin. This is a molecular process occurring on several levels. As a result, in insulin resistant 
muscle and adipose tissue, the insulin signalling pathway is impaired and glucose uptake is 
dysfunctionally low. Subsequently, pancreatic beta cells produce even higher levels of 
insulin to compensate for the low blood glucose clearance rate. Simultaneously, hepatic 
insulin resistance develops, causing impaired suppression of hepatic gluconeogenesis, which 
results in high glucose output from the liver – despite concurrent high levels of circulating 
insulin and glucose. [69] Eventually, beta cell insulin production gradually fails – due to 
defect pancreatic insulin signalling, glucose toxicity and beta cell inflammation – and the 
condition known as type 2 diabetes has been reached [70]. Below is listed a number of 
molecular events contributing to insulin resistance. They often occur simultaneously and 
many are promoted by the pro-inflammatory environment emerging in obesity, in particular 
by TNFα. 
 
 A negative feedback loop triggered by prolonged insulin receptor stimulation results 
in serine phosphorylation of IRS proteins by AKT and other kinases, which inhibits 
their ability to bind PI3K and terminates insulin signal transduction [71, 72]. 
 Degradation or inhibitory phosphorylation of IRS on serine residues by cytokines, 
impairing the insulin signalling pathway [57, 72, 73]. 
 Transcriptional suppression of the insulin receptor, IRS and GLUT4 by e.g. TNFα [59, 
60], possibly by inhibiting transcription and activity of PPARγ [74]. 
 Inhibition of insulin receptor-mediated tyrosine phosphorylation of IRS via the 
TNFα/NF-κB/SOCS pathway [75, 76]. 
 TNFα antagonises suppression of lipolysis by insulin via downregulation of 
phosphodiesterase 3B (PDE3B) [77, 78].  
 TNFα also directly affects lipolysis through suppression of HSL expression [79] and 
downregulaton of perilipins via NF-KB [80].  
 When insulin resistance has been established, subsequent failure by insulin to 
suppress basal lipolysis results in higher FA flux and subsequent lipotoxicity which 
further consolidates the insulin resistant state. 
 
To be noted, researchers have identified numerous origins of insulin resistance, besides a 
high sugar diet. Obesity itself can be the tipping point, causing dysregulated FA metabolism, 
oxidative stress or inflammation which in turn impair the function of organs involved in 
glucose disposal [81]. Inflammation with other origins may also contribute to insulin 
resistance, including failing to consume a diet sufficient in anti-inflammatory components 
such as polyunsaturated fatty acids or antioxidants. In line with this, inhibiting inflammation 
with salicylates or aspirin has positive effects on obesity-induced insulin resistance [82]. In 
addition, lifestyle factors such as night-time feeding also contribute to insulin resistance. In 
many cases, multiple pre-diabetic conditions co-occur and exacerbate each other until a 
vicious circle has developed.  
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1.6 REGULATION OF CELLULAR RESPONSE 
A cell can respond in multiple ways to internal signals or environmental changes. 
Metabolism and inflammation can be regulated on different levels and in different time-
frames. Regulation on of e.g. lipolysis or glucose uptake can take place via immediate 
stimulation of hormones which trigger signalling cascades, leading to a metabolic event, 
often within minutes. In other cases, the organism needs to adapt to a more permanent 
situation. This adaptation is often mediated by changes in gene expression via transcription 
factors, working in a time-frame of hours to days. One important subclass of transcription 
factors are nuclear receptors, which can be described as sensors of changes in hormonal or 
nutritional status and gene expression. In contrast, protein kinases are important regulators 
of both short-term effects and long-term regulation of the cellular response. In this thesis, 
we make a closer examination of the role of the nuclear receptor LXR, the transcription 
factor MAFB and the SIK kinases in human adipose tissue.  
 
1.7 NUCLEAR RECEPTORS AND LIVER X RECEPTOR 
Nuclear receptors (NRs) are transcription factors that can be activated by compounds – 
ligands – from the diet or products of internal metabolism such as bile acids, retinoids, FAs 
and cholesterol, but also by hormones such as estrogen and steroids such as vitamin D. Each 
ligand activates a distinct nuclear receptor. When activated, NRs regulate, by stimulating or 
inhibiting transcription, a large number of processes in the body, such as metabolism, 
circadian rhythm, inflammation, development, growth and reproduction. [83]. Humans 
express 48 different NRs divided into six families (NR1-6) [84]. Several NRs have been 
implicated in metabolic disease. 
 
NRs have a distinct mechanism of action. Once bound and activated by their ligands, they 
bind the DNA at their respective response elements and promote or inhibit transcription. 
Most NRs are permanently present in the nucleus and presumed to be constitutively bound 
to the DNA, whereas some (mostly steroid receptors) translocate to the nucleus upon 
extranuclear ligand binding in the cytoplasm. Co-factors are an important part of the 
process and are proteins that can act as co-repressors and co-activators. Co-repressors bind 
as protein complexes to the NR when there is no ligand bound. When a ligand binds, the co-
repressor complex dissociates and is replaced by co-activators. Subsequently, this promotes 
arrival and binding by the transcriptional machinery, and transcription is initiated. [85] The 
capacity of nuclear receptors to turn gene expression on or off, and to be bound by ligands 
make them appealing candidates for the drug industry and the treatment of diseases such 
as type 2 diabetes and atherosclerosis.  
 
The NR1 family of nuclear receptors comprises e.g. PPARγ – a master regulator of 
adipogenesis – and the Liver X Receptors (LXRs). The Liver X Receptors (LXR) belong to the 
largest superfamily, NR1 [86]. Its two isoforms (LXRα and LXRβ) are encoded by the NR1H3 
and NR1H2 genes, respectively, and share 78% identity in amino acid sequence in their DNA- 
and ligand-binding domains [87]. LXRβ is ubiquitously expressed while LXRα is highly 
expressed in tissues with metabolic function such as liver, muscle and adipose tissue [88]. 
When the term LXR is used in this thesis without specification of isoform, both isoforms are 
intended. 
 
LXR can be endogenously activated by oxysterols such as 22-R-hydroxy-cholesterol (22-R-
HC). Oxysterols form when cholesterol is oxidized which takes place both enzymatically and 
by auto-oxidation [89]. LXR can also be activated by synthetic ligands, of which GW3965 and 
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T0901317 are commonly used. LXR dimerises with retinoic X receptor (RXR), then bind as a 
heterodimer to LXR response elements (LXREs) in the DNA and promote or transrepress 
transcription of its target genes. LXREs consist of direct repeats of the sequence 5’-AGGTCA-
3’ which is separated by four nucleotides. LXR can heterodimerise with RXR both in the 
absence or presence of RXR ligands and it belongs to the Class II NRs, which are 
constitutively located in the nucleus. LXR has a number of co-factors. Among the best 
characterised are the co-repressors Nuclear Receptor Corepressor (NCoR) and Silencing 
Mediator of Retinoic Acid and Thyroid Hormone Receptor (SMRT). NCoR/SMRT is a co-
repressor complex which binds to LXR in the absence of ligands. The complex is released and 
dissociates after ligand binding, allowing transcription occur. In the event of transrepression, 
LXR is targeted by small ubiquitin-like modifier (SUMO)-ylation in the combination of ligand 
binding, upon which co-repressors bind and transcription of the target gene is inhibited [90]. 
 
LXR has been shown to be an important regulator of cholesterol metabolism, especially 
reverse cholesterol transport, a process where cholesterol is transported from peripheral 
tissues to the liver by efflux through specific transporters such as ATP-binding cassette 
proteins ABCA1 and ABCG1. LXR strongly promotes transcription of both transporters. In 
addition, LXR has also been shown to repress certain inflammatory genes [91] and have 
protective properties in neurodegenerative disease [92]. Moreover, LXR has been implicated 
in lipid and glucose metabolism. In the liver, LXR stimulates the expression of lipogenic 
genes such as SREBP1c, SCD1 and FASN. In human adipocytes, LXR influences both lipid and 
glucose oxidation [93]. In a study using 3T3-L1 adipocytes and mice, LXR has also been 
shown to induce lipolysis and lead to elevated serum glycerol [94]. In murine models, LXR 
has also been reported to be a regulator of glucose metabolism. Most studies observe a 
positive effect on glucose uptake and insulin action in adipocytes, but data from different 
laboratories are largely inconsistent. Both human and mice possess an LXRE in the GLUT4 
promoter [95] and its expression is promoted by LXR in 3T3-L1 adipocytes [96]. In line with 
those data, LXR was found to increase basal and insulin-stimulated glucose uptake in 3T3-L1 
adipocytes [94, 96]. Although, it has also been suggested that the positive effect on glucose 
uptake by LXR might be short-lived since upregulation of GLUT4 expression was transient in 
mice fed LXR-agonist [95]. In one study, only basal glucose uptake was increased, whereas 
insulin-stimulated uptake was unaltered [94]. Another study reports an increase in GLUT4 
expression after LXR stimulation but no effect on glucose uptake in subcutaneous adipose 
tissue from rats [97]. The few studies focusing on LXR in human adipocytes also observe 
conflicting outcomes. In the human adipocyte-like cell line SGBS, LXR stimulation promoted 
expression of GLUT4 [95], and in LiSa cells (a visceral adipocyte model) LXR restored insulin 
sensitivity when cells were simultaneously stimulated with TNFα [98]. Conversely, a 
different study on the role of LXR in SGBS cells observed a downregulation of GLUT4 upon 
LXR activation [99]. In addition, in a report from our group, LXRα was shown to be more 
highly expressed in obese adipose tissue compared to lean [100], whereas GLUT4 is 
generally known to be suppressed in obesity. In conclusion, data on the regulation of 
glucose uptake by LXR are inconsistent. Despite the controversy, LXR has been suggested a 
potential drug target in the treatment of type 2 diabetes. 
 
1.8 V-MAF MUSCULOAPONEUROTIC FIBROSARCOMA ONCOGENE HOMOLOG B 
V-maf musculoaponeurotic fibrosarcoma oncogene homolog B (MAFB) is a transcription 
factor belonging to the Maf family of basic leucine zipper transcription factors – a family of 
oncogenes – and is expressed in many tissues in both mice and humans [101, 102]. MAFB 
has emerged as a factor important for brain segmentation [103]. In addition, MAFB has 
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been shown to be a regulator of cell fates, as it governs differentiation paths for a number 
of cell types, including macrophages, blood cells, beta cells and osteoclasts [104-108]. 
Moreover, MAFB may have a role in inflammation. In the human monocyte/macrophage 
cell line THP-1, TNFα stimulation has been reported to induce MAFB expression. In the same 
study, MAFB in turn promotes expression of MCP-1 and thus drives inflammation [109]. 
MAFB has been previously implicated in metabolic processes such as insulin and glucagon 
transcription [110, 111], which poses an interesting link to diabetes. Moreover, 
CCAAT/enhancer binding protein δ (CEBPδ) – a transcription factor implicated in early 
adipocyte differentiation – controls transcription of MAFB [112]. However, little is known 
about MAFB as a regulator of other metabolic processes, and MAFB was completely 
uncharacterised in adipose tissue. 
 
1.9 SALT-INDUCIBLE KINASAES 
The Salt-inducible kinases (SIKs) comprise a family of three members (SIK1, -2 and -3) which 
are related to AMP-activated protein kinase (AMKP). The name originates from the 
discovery of SIK1 in the adrenal glands of high salt fed rats. SIK2 and -3 were added to the 
family based on sequence homology [113, 114]. AMPK is a master regulator of cellular 
energy homeostasis and metabolism. Similarly to AMPK, the SIKs have been found to be 
regulators of metabolism and to be phosphorylated by Liver Kinase B1 [115]. An increased 
intracellular AMP/ATP ratio activates SIK2 in 3T3-L1 adipocytes [116], a situation which 
mimics a cellular energy deficit and also activates AMPK. SIKS have been implicated in the 
regulation of a large number of cellular processes in different tissues. SIK2 has been shown 
to regulate insulin secretion [117], and suppress gluconeogenesis in the liver [118] as well as 
inhibit lipogenesis in 3T3-L1 adipocytes[116]. Together, this indicates a possible role of SIKs 
in metabolic disease. 
 
SIKS exert their mechanism of action through phosphorylation of transcriptional regulators 
and have a number of different targets. CREB-regulated transcription coactivator (CRTC) -1, -
2 and -3 and histone deacetylase (HDAC) -4 and -5 (Class II HDACs) are among the 
established substrates for the SIK proteins. CRTC phosphorylation by SIKs sequesters them 
in the extranuclear space. When SIKs are phosphorylated and inactivated by PKA, CRTCs 
translocate to the nucleus where they regulate CREB targeted transcription. In a similar 
fashion, HDACs are also prevented from entering the nucleus when phosphorylated by SIKs. 
HDACs suppress transcription by deacetylation of histones, which results in local 
condensation of chromatin and reduced gene expression. Consequently, this suppression is 
inhibited by SIKs. [119-123]  
 
SIK1 is most highly expressed in adrenal glands whereas SIK3 is widely expressed in a 
number of tissues. SIK2 is most abundant in adipose tissue, although its role in adipocytes 
has only recently been studied more extensively. SIK2 expression is increased during 
adipogenesis and is higher in adipose tissue from the obese and diabetic db/db mice than in 
wild-type mice [114]. Recently, CRTC2, CRTC3 and HDAC4 have been confirmed as SIK2 
substrates in murine and human adipocytes. In the same study, basal glucose uptake was 
augmented in primary rat adipocytes expressing wild-type SIK2 compared with adipocytes 
expressing mutated loss-of-function SIK2. However, insulin-stimulated glucose uptake in 
these cells was not affected. [124] In another recent investigation, SIK2 knockout mice 
displayed higher glucose levels in the blood than wild-type mice, and had suppressed 
glucose tolerance. GLUT4 was downregulated in the SIK2 knockout mice and glucose uptake 
in adipocytes was impaired [125]. Taken together, SIK2 emerges as an interesting candidate 
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in obesity and diabetes research. However, the role of SIK2 in obesity and adipocyte glucose 
metabolism is incompletely understood and has not been previously investigated in 
humans. 
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2 AIMS AND HYPOTHESES 
 
2.1 GENERAL AIMS 
The general aim of the work comprising this thesis is to extend the knowledge about 
adipose tissue, an organ of immense importance for the development of modern diseases, 
yet incompletely characterised in humans. More specifically, finding factors that may serve 
as possible drug targets or markers for metabolic disease originating in adipose tissue could 
be of importance for future diagnosis and treatment strategies. We have studied three 
factors with potential roles in obesity-associated metabolic complications; 1) LXR, which has 
previously been implicated in adipocyte metabolism in rodent models, 2) MAFB and 3) SIK2 
which we found to have differential expression in adipose tissue from obese humans 
compared to lean. This differential expression might indicate involvement in the 
development of obesity or its secondary complications. In this thesis, we wished to establish 
the role of these factors in adipose tissue function. 
 
2.2 STUDY-SPECIFIC AIMS 
I. The aim of the first study was to investigate the role of LXR in the regulation of 
lipolysis. 
II. The aim of study two was to study how LXR affects human adipocyte glucose 
uptake. 
III. The aim of the third study was to characterise the function of MAFB in human 
adipocytes and monocytes. 
IV. The aim of study four was to examine the regulation of SIKs by obesity and the 
influence on glucose uptake by SIK2. 
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3 METHODOLOGY 
The methods and materials used for each study have been described in their corresponding 
papers. In this chapter, interesting aspects of a few selected methods not covered therein 
will be addressed. 
 
3.1 CELL CULTURE MODELS 
 
3.1.1 Primary adipocytes 
For the majority of the experiments in this thesis, primary cells isolated from human adipose 
tissue were used. Adipose tissue was obtained from liposuctions or biopsies. In total, three 
different primary cell culture systems listed below were employed. 
 
3.1.1.1 Primary in vitro differentiated pre-adipocytes 
Total SVF of adipose tissue was cultured and differentiated in vitro into adipocytes, without 
proliferation. After 3-4 days in adipogenic media, immune cells die off and are washed away 
during media changes. Only cells with adipogenic capacity remain in the culture. The cells 
with adipogenic capacity within SVF are stimulated to develop into adipocytes by activating 
the adipogenic program. Rosiglitazone is a synthetic ligand of PPARγ, the main factor driving 
adipogenesis, and a crucial component of adipogenic culture medium. In addition, insulin is 
also pro-adipogenic and added to the medium.  The major advantage of SVF-derived 
adipocytes is that some characteristics of the donor tissue are preserved even after in vitro 
differentiation [126, 127]. Thus, experiments conducted on this cell system retain a certain 
degree of biological variation, in this aspect resembling freshly isolated mature adipocytes. 
The major disadvantages of this adipocyte system are the time consuming isolation 
procedure and limited supply of donor tissue. In this thesis, the term SVF-derived adipocytes 
will be used to describe these cells. 
 
3.1.1.2 Human mesenchymal stem cells 
Human mesenchymal stem cells (hMSCs) were isolated from the stromal vascular fraction 
(SVF) of adipose tissue, expanded in vitro and differentiated into adipocytes. hMSCs can be 
differentiated into myocytes, osteocytes, chondrocytes and adipocytes. FGF2 is added to 
the culture medium to stimulate proliferation and adipogenesis is induced using 
rosiglitazone and insulin as for SVF-dervied adipocytes. Adipocytes differentiated from 
hMSCs display an adipocyte phenotype in their lipolytic response, secretion of adipokines 
and response to insulin [127-130]. hMSC cultures are expandable and advantageous to use 
when large amounts of cells are needed and when a minor degree of biological variation is 
desired. 
 
3.1.1.3 Freshly isolated mature adipocytes 
Mature adipocytes were isolated from adipose tissue by collagenase. Mature adipocytes do 
not attach to cell culture dishes due to their high lipid content and have to be cultured 
floating. Methods of assessing e.g. glucose uptake in these cells have been evaluated [131]. 
The advantage of studying mature adipocytes from human donors is that they more than 
other adipocyte cell systems resemble adipocytes in vivo. The drawback is their fragility in 
culture medium and that they cannot be cultured longer than 72 h, as determined 
empirically in our lab. Also, there are limitations to the type of treatments and experimental 
procedures that can be applied for mature adipocytes. 
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Both hMSC-derived adipocytes and SVF-derived adipocytes in culture differ from primary 
mature ex vivo adipocytes. For example, they have multiple lipid droplets whereas mature 
adipocytes have one large integral TG reservoir. This may affect their function. Further, a 
study comparing gene expression profiles assessed during in vitro and in vivo adipogenesis 
reveal a number of genes that are differentially regulated [132]. In addition, the 
differentiation cocktail and culture conditions of all cell cultures lack the diversity of 
molecules that surrounds cells in vivo and this may have an indiscernible impact on their 
function. 
 
3.1.2 Cell lines 
In paper I and IV we have used immortalised cell lines. 
 
3.1.2.1 3T3-L1 adipocytes 
The murine 3T3-L1 adipocyte cell line was employed for one comparative experiment in 
paper I. In the field of adipocyte research, it is a commonly employed culture model. 3T3-L1 
is an immortalised cell line of pre-adipocytes originally derived from mouse embryos [126]. 
Like human SVF-derived preadipocytes differentiated in vitro, 3T3-L1 adipocytes also exhibit 
multiple lipid droplets. In its character of a cell line, it has an altered cell cycle mechanism 
and a high degree of spontaneous mutations. The main advantage of this model is its cost-
effectiveness and low degree of biological variation. A drawback of using 3T3-L1 cells is their 
murine origin. Rodents and humans biology differ substantially in some aspects, and there 
are known differences between murine and human adipose tissue function. Interspecies 
differences will be discussed in section 3.2. Unlike SVF-derived and hMSC adipocytes, 3T3-L1 
are committed and pre-programmed for adipogenic differentiation. 
 
3.1.2.2 THP-1 cells 
The human monocyte cell line THP-1 was used for paper III. As 3T3-L1, THP-1 is an 
immortalised cell line. THP-1 monocytes can be differentiated into macrophages in culture. 
In adipose tissue in vivo, fully differentiated macrophages exhibit different polarizations – 
M1 for classically activated (pro-inflammatory) macrophages, and M2 for alternatively 
activated (anti-inflammatory) macrophages. However, after inducing differentiation 
according to the standard protocol, THP-1 cells display a non-polarized, non-activated (M0) 
phenotype [133]. This concern is however not applicable to this thesis since THP-1 cells were 
studied as undifferentiated monocytes. As mentioned in section 1.2.3, the macrophage 
population in vivo is most likely more complex than the M1/M2 division implies. 
 
3.2 INTERSPECIES DIFFERENCES 
When selecting cell system or animal model for a research study, awareness of the 
advantages and disadvantages of different options is important. Using in vivo animal (often 
mouse) models provides the obvious advantage of being able to study a factor in the 
physiological context, and is a necessary step prior to human drug trials. However, there are 
a number of known differences between human and mouse biology. A few examples of 
discrepancies between human and mice specific for adipose tissue function are listed below. 
 
 Epididymal fat is an often studied adipose tissue depot in mice, partly because it is 
easy to isolate. However, there is no corresponding fat depot in humans and as 
different fat depots have been shown to differ in certain aspects this raises concerns 
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about the relevance of epididymal fat for studies where results are extrapolated to 
humans [10]. 
 Omental fat – a rather large and important visceral fat depot in humans –, on the 
other hand, is barely present in mice [10]. 
 In humans, lipolysis can be negatively regulated by α2 adrenergic receptor signalling. 
However, this pathway does not exist in rodents [42]. 
 In human adipose tissue, lipolysis can be stimulated by natriuretic peptides, whereas 
this function has not been found in rodents [134]. 
 Genome-wide analyses of PPARg binding sites reveal that a high number of binding 
sites are different in the mouse and human genome [135, 136].  
 Interestingly, mice have a higher adipocyte turnover – 0.6% per day in mice [137] vs. 
8% per year in humans [11]. Although, this might simply reflect their shorter life-
span. 
 The immune system of mouse models often employed in obesity-studies differs 
from that of humans in a number of respects [138]. Since immune cells populate 
adipose tissue, and there is extensive cross-talk between adipocytes and immune 
cells, this may be of importance to adipocyte research. 
 
An additional concern specific to obesity research is the often studied obese mouse models 
which lack leptin production (ob/ob mice) or a functional leptin receptor (db/db mice). They 
are highly convenient to work with but differ from common human obesity. Leptin 
deficiency is a rare condition in humans and does not contribute to the epidemic of obesity. 
As mentioned in section 1.3.4, leptin stimulates satiety. But it also affects energy 
expenditure, atherogenesis, fertility, insulin sensitivity, and neurodegenerative disease [46]. 
This may influence study results in ways that are hard to predict. 
 
Conclusively, when a factor has solely been studied in animal models, it is often considered 
a limitation. However, choosing to work exclusively with human material is time-consuming 
and costly. Yet there are major important advantages to use human cells when possible. 
 
3.3 STUDYING GENE EXPRESSION 
The phenotype of a cell is formed by its gene expression profile. Gene expression controls 
everything from physical appearance to its function. The study of gene expression is an 
especially important part of thesis as three of the studies concerns transcription factors. We 
have used two different methods for mRNA quantification and two methods for 
quantification of protein. Advantages and disadvantages of these methods will be briefly 
discussed below. 
 
3.3.1 Microarray profiling 
Genome-wide mRNA expression profiling by microarray provides the possibility to compare 
mRNA or miRNA expression of a large number of transcripts (>20 000) between different 
conditions. In paper I and II, microarrays are used to examine global mRNA and miRNA 
expression. Although other alternative methods to determine global levels of transcripts 
were available at the time, such as RNA sequencing (RNA-seq) or Cap Analysis of Gene 
Expression (CAGE), they were not as established and evaluated as microarrays. Microarrays 
also has additional advantages; they are cheaper, require less biological material and 
expression data are easily comparable between different data sets. Microarray data is easily 
processed using computer software and information on signalling pathways and biological 
processes can easily be extracted. Like with other methods determining RNA expression, 
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comparison of the absolute quantification between genes is not possible due to distinct 
binding affinities of the different mRNA/miRNA transcripts to their respective probes. 
Following microarray profiling, quantitative real-time polymerase chain reaction (qRT-PCR) 
is often used as a validation method for specific genes of interest. 
 
3.3.2 Quantitative real-time PCR 
Quantitative real-time PCR (qRT-PCR) is used to quantify certain transcripts of interest using 
specific primers and nucleotide-binding dyes. In short, RNA is purified from cells or tissue 
and reverse transcribed into cDNA. The transcript is amplified during multiple cycles by Taq 
polymerase and primers that bind to a sequence which is specific to the transcript of 
interest. In the papers of this thesis, we have used two different methods for detection; 
Taqman and SYBR green assays. In a Taqman assay, probes specific to a certain sequence 
are labelled with a fluorescent dye and a quencher, which absorbs the fluorescence. During 
elongation, the probe is bound to the cDNA and as the polymerase reaches the probe, it is 
degraded and the quencher is simultaneously released from the fluorophore, allowing it to 
emit fluorescence. Taqman assays require a larger amount of RNA and is expensive, 
compared to the SYBR green method. In a SYBR green assay, the dye binds non-specifically 
to double-stranded DNA. Due to the unspecific nature of the dye, it also binds 
indiscriminately to any primer-dimers and unspecific PCR products that might form. 
Therefore, SYBR green primers should be verified in a dissociation curve to detect any 
unspecific products. Fluorescence is recorded by a PCR instrument and compared by the 
researcher to that of a housekeeping gene in the same samples. 
 
3.3.3 Western blot 
Western blot is a method widely used to measure protein expression based on protein size 
compared to a known standard. Proteins are separated by size using electrophoresis and 
transferred to a membrane which is incubated with primary antibodies binding the protein 
of interest. Incubation with a secondary antibody conjugated to enzymes or fluorophores 
then binds to the primary antibody and detection is performed using chemiluminescence or 
fluorescence. A densiometric comparison of protein band size and density can be made on 
the resultant blot. The band density can also be measured by computer software and 
compared to that of a housekeeping protein. However, it is not only semi-quantitative due 
antibody-target properties. It also has other drawbacks; it is dependent on specific 
antibodies that bind the denatured protein with high affinity. Post-translational 
modifications of a protein may alter the perceived protein size compared to the known 
standard. In addition, it is time-consuming and the success of the procedure can be 
unpredictable. 
 
3.3.4 Enzyme-linked immunosorbent assay 
In contrast to Western blot, enzyme-linked immunosorbent assay (ELISA) is highly 
quantitative and quick to perform. In ELISA, protein lysates are loaded onto a microplate 
pre-coated with antibodies binding the target protein. The protein is subsequently probed 
with a detection antibody and a secondary antibody linked to an enzyme, e.g. horseradish 
peroxidase (HRP). HRP will catalyse a colour change of a substrate, upon which this colour 
can be measured spectrometrically. Colour density indirectly corresponds to protein 
expression and is often normalised to the amount of loaded protein. ELISA requires less 
material than western blot, and conditioned medium can be used for detection of secreted 
proteins. ELISA is dependent on a very high specificity of the antibody. Should unspecific 
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binding to other proteins occur, this is not by any means visible and the quantification will 
be faulty. Nevertheless, ELISA serves a good compliment to Western blots. 
 
3.3.5 Correlations of mRNA levels and corresponding protein expression 
mRNA levels do not always reflect the protein levels. Regulation of translation or translation 
rate, protein half-life and secretion are some events that all lead to a non-linear relationship 
between mRNAs and protein, although this varies greatly between individual proteins [139]. 
In addition, the amount of protein does not translate to protein function and protein activity 
should ideally be investigated. Therefore, one should whenever possible quantify both 
mRNA and protein amounts as well as protein activity when studying the biological function 
associated with the protein in question. However, mRNA levels alone do provide interesting 
clues despite not always being accompanied by the matching variations in protein 
expression, since it offers information about the transcriptional regulation of a certain gene, 
or of the activity of a certain transcription factor. 
 
3.4 METABOLIC METHODS 
 
3.4.1 Glucose uptake 
Three of the four thesis papers include measurements of glucose uptake. There are several 
methods to study glucose uptake into adipocytes. In paper II and IV, we used a classical 
glucose uptake protocol designed for adipocytes in culture. In this protocol, 2-Deoxy-D-[1-
3H]-glucose is added to the cells in the absence or presence of insulin, upon which basal and 
insulin-stimulated glucose uptake can be quantified. 2-Deoxy-D-[1-3H]-glucose is a 
radioactive, non-metabolisible form of glucose. Thus, it cannot be incorporated into lipids 
and the only factor being measured is glucose uptake itself. However, for paper III we 
developed a second protocol, measuring total glucose uptake based on a lipogensis protocol 
[140]. For this procedure, we use D-[3-3H]glucose which is metabolised by the cell and 
incorporated into lipids. Also, insulin stimulation is prolonged compared to the glucose 
uptake protocol described above – 2 hours vs. 15 minutes. This provides a higher and more 
robust insulin-response. In human adipocytes, glucose uptake is rate-limiting for lipogenesis 
at the concentrations of glucose used in this protocol [141] and thus, measuring total 
glucose uptake after stimulation of lipogenesis reflects the cell’s ability to transport glucose 
across the plasma membrane. Consequently, when stimulating with insulin, we are 
indirectly measuring insulin signalling and GLUT4 translocation.  
 
Insulin is added to the adipocyte culture medium as an inducer of adipogenesis. To reset 
insulin sensitivity in our cells prior to glucose and lipogenesis assessments, we removed 
insulin for a period of time prior to insulin stimulation. In SVF-derived adipocytes, 3 h 
incubation in insulin-free medium was enough to produce an insulin response. However, 
hMSC-derived adipocytes have a higher insulin concentration in culture medium and require 
a longer time in insulin-free medium to reverse their insulin resistance. Thus, we optimised 
incubation times in medium without insulin and found 48-72 h to be optimal [127]. 
 
3.4.2 Lipolysis 
In paper II we studied the effects of LXR stimulation on adipocyte lipolysis. Lipolysis was 
assessed during 3 h incubation of cultured adipocytes in medium with or without lipolytic 
agents. Isoprenaline is a β adrenergic agonist with structural resemblance to adrenaline 
and was used in our study to stimulate lipolysis. When assessing lipolysis in adipocytes, 
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glycerol release into the conditioned medium is quantified. The reason for this is briefly 
discussed earlier – adipocytes do not express the enzyme required for re-esterification of 
glycerol to FAs into TGs [41]. Thus, released glycerol represents an accurate account for 
the rate of lipolysis. Glycerol is also easily measurable enzymatically or using a 
bioluminescence method. Of note is that albumin has to be supplied into the conditioned 
medium as a carrier for the non-water soluble liberated FAs, or the cells will be subject to 
lipotoxic effects.  
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4 RESULTS 
 
4.1 PAPER I 
As mentioned in the introduction, lipolysis is one of the main functions of the adipocyte, 
resulting in the release of FAs to be utilised by other tissues. In obesity, this process is 
dysregulated and while stimulated lipolysis is blunted, basal lipolysis is enhanced. LXR has 
previously been implicated in the regulation of lipid turnover in mice and murine cell 
models. When activating LXR in 3T3-L1 adipocytes, basal lipolysis is augmented [94]. 
However, the role of LXR in lipolysis in human adipocytes had not been studied. We 
hypothesized that LXR also regulates lipolysis in human adipocytes. We therefore set out to 
determine the effects of LXR activation on lipolysis in human fat cells.  
 
Initially, we stimulated human SVF-derived adipocytes using the LXR specific agonist 
GW3965 and observed a concentration-dependent increase in lipolysis as measured by 
glycerol released into conditioned medium. Using mRNA microarray profiling, qRT-PCR and 
western blot, we identified two genes with major importance for lipolysis which were 
downregulated by GW3965 treatment; hormone-sensitive lipase HSL and PLIN1. 
 
Next we investigated the effects of LXR activation on the cellular localisation of HSL and 
PLIN1 by immunostaining. Interestingly, lipid droplet-associated PLIN1 proteins decreased in 
number. Also, when quantifying the ratio of HSL to PLIN present in the cells, it turned out to 
increase dramatically upon LXR stimulation. This indicated that HSL activation was 
enhanced, despite the observed downregulation of HSL expression. It also implies that the 
general lipid droplet morphology was altered.  
 
We continued to investigate HSL sites that are targets of phosphorylation and activation of 
its lipolytic function. When quantifying the total downregulation of HSL by LXR and 
comparing it to the levels of phosphorylated HSL, the ratios were not altered upon LXR-
stimulation. We further stimulated adipocytes with GW3965 with or without a combination 
of the HSL inhibitor BAY. Intriguingly, inhibiting HSL activity completely blocked the effects 
of LXR on glycerol release. Hence, we could conclude that enhanced lipolysis by LXR in 
adipocytes still relied on HSL activity, despite the downregulation of HSL expression. 
 
We continued to explore the role of PLIN1 in LXR-mediated lipolysis. PLIN1 knockdown lead 
to increased glycerol release. When combining PLIN1 knockdown with GW3965 treatment, 
the effects of GW3965 were gone. From this we drew the conclusion that PLIN1 was a main 
player in the regulation of lipolysis by LXR. Using chromatin immunoprecipitation we also 
found that LXR is recruited to the proximal promoter of PLIN1, and binds to intron 1 of the 
LIPE gene (encoding HSL). We were also able to demonstrate that LXRα is the major isoform 
mediating the effects or LXR on lipolysis. 
 
In summary, we are able to demonstrate that LXR augments basal lipolysis in primary 
human adipocytes. The findings of paper I are depicted in Fig. 3.  
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Fig. 3. Proposed mechanism of LXR-mediated effects on lipolysis. 
 
4.2 PAPER II 
As discussed in section 1.5, the diagnosis of type 2 diabetes means in part that muscle and 
adipose tissue have lost their ability to properly take up glucose from the blood. LXR has 
been extensively studied in the context of glucose metabolism in murine adipose models 
such as 3T3-L1 mouse-derived adipocytes and LXR knockout mice. Several studies have 
found that LXR promotes glucose uptake in murine adipocytes (summarised in section 1.7). 
This has opened up interest for LXR as a drug target in the treatment of diabetes. However, 
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the role of LXR on glucose uptake has only briefly been studied in human adipocytes. Thus, 
we decided to investigate the effects of LXR stimulation on glucose uptake and insulin 
signalling in primary human adipocytes. For this study we used three different human 
adipocyte cell systems; 1) SVF-derived adipocytes, 2) hMSCs-derived adipocytes and 3) 
primary mature ex vivo adipocytes. 
 
Initially, we performed a genome-wide analysis of the effects on mRNA and miRNA 
expression after LXR stimulation, to search for transcriptional alterations of any genes or 
miRNAs known to be involved in glucose uptake. This was performed by microarray profiling 
of human adipocytes treated with the LXR agonist GW3965. Thus, we focused on mRNA 
expression. The overall results of the mRNA microarray analysis placed metabolic pathways 
in the top of listed regulated biological processes. 
 
A closer examination of the insulin signalling pathway revealed that LXR stimulation 
negatively altered the expression levels of several genes of the insulin signalling cascade. 
More specifically, AKT2, SORBS1 (encoding CAP) and CAV1 – all important for insulin 
signalling – were downregulated compared to control treatment. GLUT1 (encoded by 
SLC2A1) and GLUT4 (encoded by SLC2A4) are glucose transporters responsible for basal 
and insulin-stimulated glucose uptake in adipocytes, respectively. SLC2A1 was upregulated 
by LXR activation, whereas SLC2A4 (encoding GLUT4) was unaffected. Thus, we were able 
to confirm the upregulation of SLC2A1 observed in previous studies. Interestingly, the 
lipogenic genes ACC1, SCD1 and FAS were unaffected by LXR activation in this microarray, 
contrary to previous reports in hepatocytes and murine cell lines. AKT2, CAP and CAV1 
were also downregulated on protein level, as determined using western blot. 
 
Next, we studied the effects of LXR activation on glucose uptake in human adipocytes. We 
stimulated SVF-derived adipocytes with the LXR agonist GW3965 and measured basal and 
insulin-stimulated glucose uptake. Basal uptake remained unaffected whereas insulin-
stimulated glucose uptake was suppressed upon LXR activation. We were curious to 
investigate if the weight status of the human donor subjects would have an effect on the 
outcome. We discovered that LXR significantly suppressed glucose uptake in adipocytes 
from overweight donors only, in both SVF-derived adipocytes and mature ex vivo 
adipocytes. 
 
AKT2 is universally considered a protein of very high importance for transduction of the 
insulin signalling pathway. Therefore, we turned our focus to this protein. We studied 
effects of LXR activation on phosphorylation of AKT2 at Ser474. As expected, AKT2-P-ser474 
increased dramatically upon insulin stimulation. In combination with GW3965 stimulation, 
phosphorylation at this site was reduced to same extent as the downregulation of total 
AKT2 protein, suggesting that LXR mainly affects protein expression and not activation of 
AKT2. The fact that we observed the same level of LXR-mediated inhibition of insulin-
stimulated glucose uptake as of phosphorylation of AKT2 also suggests that AKT2 could be 
the major factor through which LXR impairs insulin-stimulated glucose uptake. We also 
demonstrate that LXRα turned out to be the main isoform mediating the suppression on 
AKT2 expression. 
 
Reduced insulin-stimulated glucose transport should in theory be associated with reduced 
translocation of GLUT4 to the plasma membrane. Therefore, we stimulated adipocytes with 
LXR agonist and isolated the plasma membrane fraction. A western blot using plasma 
 24 
membrane proteins showed that LXR stimulation indeed caused a diminished translocation 
of GLUT4. 
 
In summary, we demonstrate that LXR-stimulation inhibits insulin-induced glucose uptake in 
adipocytes from humans on the obese spectrum. This inhibition may be mediated by 
suppression of AKT2, CAP and CAV1 expression. 
 
The findings of paper II are illustrated in Fig. 4.  
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Fig. 4. Proposed mechanism of LXR-mediated effects on glucose uptake. GSV; GLUT4 storage vesicle. 
 
4.3 PAPER III (MANUSCRIPT) 
After publishing paper II, interesting data emerged from the functional annotation of the 
mammalian genome 5 project, where CAGE analysis was used to quantify genome-wide 
transcriptional profiles of 150 human tissues and cell types [142]. Extracting the expression 
of known human transcription factors from this data set reveals LXRα as the factor with the 
highest enrichment in mRNA expression in adipocytes (114x higher as compared to the 
median expression in all tissues). MAFB turned up in the top five with the highest expression 
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in adipocytes. (Fig. 5.) This lead to our hypothesis that MAFB may be important in adipocyte 
biology. In a previously published microarray dataset comparing gene expression in adipose 
tissue between obese and non-obese individuals, we also found MAFB to be regulated by 
obesity. MAFB had not been implicated in obesity or studied in adipose tissue, and together, 
these initial findings intrigued us to characterise its role in human adipose tissue. 
 
 
 
Fig. 5. Enrichment of MAFB mRNA expression in adipocytes relation to the median expression in 150 human 
tissues. TPM; tags per million. Image prepared by Niklas Mejhert. 
 
 
Initially, we confirmed higher expression of MAFB in obese subjects compared to lean in a 
second cohort. This cohort also comprised obese individuals diagnosed with the metabolic 
syndrome, and in these subjects, MAFB was even more highly expressed than in 
metabolically healthy obese subjects. The same regulation pattern occurred in a third and a 
fourth cohort where MAFB was downregulated after weight loss. These findings possibly 
imply that MAFB might be involved in the dysregulation of metabolism and/or 
inflammation. 
 
Next, we investigated if MAFB was associated with any metabolic features of human 
subjects in a cohort of 56 subjects. MAFB correlated negatively with insulin sensitivity 
measured as insulin-stimulated lipogenesis in adipocytes, as well as with isoprenaline-
induced lipolysis which indicates that MAFB might be associated with an unfavourable 
metabolic profile.  
 
The findings described above intrigued us to make an extensive investigation of the role of 
MAFB in adipocyte function and metabolism. We found that MAFB was strongly induced 
during adipocyte differentiation. To study the importance of MAFB for metabolism, we 
performed siRNA-mediated knockdown of MAFB. MAFB knockdown did not affect 
adipogenesis, lipid accumulation, basal lipolysis, nor basal or insulin-stimulated lipogenesis. 
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However, MAFB knockdown did reverse the unfavourable effects caused by TNFα treatment 
on lipid accumulation and lipolysis. This implies that MAFB is required to fully mediate the 
effects of TNFα in these conditions and this cell system. Thus, MAFB is a mediator of 
inflammation in human adipocytes. 
 
We further studied the role of MAFB in the regulation of inflammatory gene expression in 
adipocytes and found that MAFB mediates TNFα-induced IL6 expression. In line with the 
reversal of TNFα-mediated effects on lipolysis and lipid accumulation, MAFB is seemingly 
necessary for TNFα signalling to fully induce IL-6 expression.  
 
MAFB itself has also been reported to be regulated by TNFα in macrophages [109]. Since 
TNFα release is increased in adipose tissue in obesity, we wished to study the effects of 
TNFα on MAFB expression in adipocytes. Thus, we stimulated both monocytes – the 
precursors of macrophages – and adipocytes with TNFα and measured MAFB expression. 
Interestingly, in contrast to monocytes, MAFB was downregulated by TNFα in adipocytes. 
The effects were obvious already after 6 hours of incubation, from which we drew the 
conclusions that the effects were a result of direct TNFα signalling.  
 
Finally, we observed that MAFB is 13 times more highly expressed in 
monocytes/macrophages than in adipocytes from primary adipose tissue, and correlates 
strongly and positively with the macrophage markers CD14 and CD68 as well as TNFα mRNA 
expression in adipose tissue explants. All in all, these data suggest that MAFB is a marker of 
inflamed adipose tissue as well as the level of macrophages infiltration. 
 
The findings of paper III are depicted in Fig. 6. 
 
 
Fig. 6. Proposed regulation and mechanism of action of MAFB in monocytes/macrophages and adipocytes. 
 
4.4 PAPER IV (MANUSCRIPT) 
The Salt-inducible kinases (SIKs) SIK1, 2 and 3 are related to AMPK and influence gene 
expression by phosphorylating proteins that in turn regulate transcription such as HDACs 
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and CRTCs. SIKs (mainly SIK2 and SIK3) have previously been shown to be highly expressed 
and to regulate various metabolic functions in murine adipose tissue. However, SIK data 
from human adipose tissue is lacking. We hypothesized that SIKs are of importance in 
human adipose tissue and aimed to investigate its regulation by obesity and its role in 
glucose uptake. 
 
Initially, we wished to investigate the relative expression levels of the three SIK proteins in 
adipocytes from human subjects. The by far most predominant isoform expressed in 
adipocytes was SIK2. Next, we quantified the levels of SIK2 and 3 in intact subcutaneous 
adipose tissue from non-obese and obese subjects. Interestingly, SIK2 and SIK3 expression 
was lower in obese. In addition, SIK2 and SIK3 mRNA was increased after weight loss by 
bariatric surgery. SIK2 mRNA expression also correlated negatively with HOMA-IR. These 
data suggest that SIK2 might be a factor associated with a favourable metabolic profile in 
human adipose tissue.  
 
From this point in the investigation, focus turned to SIK2 as it was most highly expressed in 
adipocytes, and also was affected by obesity and weight loss more dramatically than SIK3. 
We thus set out to further characterise the role of SIK2 in obesity. 
 
We hypothesised that the reason for suppressed SIK2 expression in obesity could be related 
to the pro-inflammatory environment. Therefore, we mimicked the influence of inflamed 
tissue on adipocytes by treating them with TNFα and studied the effects on SIK2 mRNA and 
protein expression. In line with our hypothesis, SIK2 expression was downregulated by TNFα 
on both mRNA and protein level.  
 
Since SIKs have been implicated in the regulation of glucose metabolism in rodents, we 
wished to determine the role of SIK2 on glucose uptake in human adipocytes. We treated 
adipocytes in culture with a pan-SIK inhibitor and measured glucose uptake. Since the 
expression level of SIK2 greatly exceeded that of SIK1 and -3, we made the assumption that 
any effects observed following SIK-inhibition treatment in all probability could be attributed 
to inhibition of SIK2. Interestingly, both basal and insulin-stimulated glucose uptake was 
attenuated upon SIK inhibition. These data support the significance of the correlations with 
HOMA-IR and decreased expression of SIK2 in obese subjects. In addition, phosphorylation 
of the SIK substrates HDAC4 and CRTC2 was similarly reduced upon inhibitor treatment. 
 
The findings of paper IV are illustrated in Fig. 7. 
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Fig. 7. TNFα-regulation of SIK2 and SIK2-mediated effects on gene expression in adipocytes. 
 
In addition to the data presented in paper IV, we have investigated correlations of SIK2 
mRNA with other variables available in our clinical cohorts which could give clues to the 
function of SIK2 in adipose tissue. In unpublished data, SIK2 mRNA expression correlated 
positively with adipocyte cell volume from humans with varying BMI. We also found a 
negative correlation between SIK2 and SLC2A4 mRNA (Fig. 8.) 
 
 
 
Fig. 8. Correlations of SIK2 mRNA with SLC2A4 mRNA expression and cell volume.
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5 DISCUSSION 
In paper I and II, we find that LXR is an inducer of basal lipolysis and a suppressor of insulin-
stimulated glucose uptake in human adipocytes.  
In paper I, we found that PLIN1 and HSL were downregulated by LXR in our cell system. 
However, the level of HSL phosphorylation was not affected. Our observation of increased 
spontaneous lipolysis with a simultaneous drop in PLIN1 levels has been reported previously 
[143-145]. With regards to HSL, knockdown of this protein has been shown to either 
suppress [146] or not affect spontaneous lipolysis [79, 147]. Since HSL phosphorylation was 
not affected by LXR, and HSL knockdown might not alter basal lipolysis, it is possible that 
suppression of PLIN1 alone (leading to an increase in HSL to PLIN1 ratio) is mediating the 
observed effects of LXR stimulation on lipolysis. Interestingly, TNFα has similar effects on 
adipocyte lipolysis – downregulating both HSL and PLIN1 [79, 80] – with a net effect of 
augmented spontaneous lipolysis. It is important to mention that HSL is known to be 
phosphorylated on multiple sites and other residues not investigated in this paper may be 
affected by LXR treatment. 
ATGL mRNA expression was not altered by LXR on the microarray, and although its co-factor 
CGI-58 was downregulated on mRNA level, we were not able to confirm it on protein level. 
It has however been reported that reduced expression of PLIN1 could lead to release of CGI-
58 from the lipid droplet, where it resides in the unstimulated state, and subsequent 
activation of ATGL. Thus, it is possible that ATGL or CGI-58 is involved in LXR-mediated 
lipolysis. 
We further found that LXR binds to the human PLIN1 and HSL proximal promoters. 
However, we did not identify any LXREs in the PLIN1 promoter and LXR did not bind to the 
weak LXREs found in the HSL promoter. Consequently, LXR can evidently bind to additional 
sequences or possibly interact with DNA through another factor. LXR has been shown to 
LXREs have predominantly been associated with positive regulation of gene expression 
[148], and as LXR binds to other sequences in the proximal promoters of LIPE and PLIN1, 
these sequences could in theory specifically promote negative regulation of LXR target 
genes.  
An mRNA microarray analysis was used both in paper I and II to identify LXR-regulated 
genes of potential interest in human adipocytes. Using computer software to highlight 
biological processes that were regulated by LXR in our cells revealed that metabolic 
pathways were among the top of regulated processes. This confirms two previous studies 
conducting genome-wide mRNA profiling of LXR effects in human cells, in hepatocytes [149] 
and macrophages [150], both found that one of the main processes regulated by LXR is lipid- 
and cholesterol metabolism. In this genome-wide analysis, a mere 364 genes were 
upregulated, whereas 1.161 genes were downregulated upon LXR activation. Since LXREs 
reportedly primarily mediate a positive gene regulation (as discussed above), this could 
hypothetically indicate that the human genome contains a large number of alternative 
binding sites for LXR. 
The role of LXR in the expression of insulin signalling proteins is previously unexplored. 
Therefore, when analysing the specific metabolic pathways regulated by LXR on the 
microarray, it was interesting to find that the expression of three proteins of presumed high 
importance for insulin signalling (AKT2, CAP, CAV1) was altered by LXR stimulation. In a 
previous report, the authors performed a microarray analysis on adipose tissue from LXR-
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agonist fed mice [151]. However, the insulin signalling pathway was not affected by LXR 
activation in that study. This implies the presence of species-specific differences in the 
response to LXR stimulation. Interestingly, Kotokorpi and co-authors [149] also found that 
the effects of LXR stimulation differed in human and murine hepatocytes, confirming our 
observation of interspecies differences. 
In the microarray, SLC2A1 was upregulated by LXR activation, which is a confirmation of 
findings in previous studies. However, translation into its protein GLUT1 remained unaltered 
by LXR. This is in line with unaltered basal glucose uptake after LXR activation. Possible 
reasons for the discrepancy between mRNA transcription and protein expression from the 
same gene are discussed in section 3.3.5. In addition, the total expression level of GLUT1 is 
low in adipocytes. Also, some GLUT4 is believed to be present on the plasma membrane 
even in the non-stimulated state and could contribute to basal glucose uptake. 
In both paper I and II, LXRα was the isoform mediating the effects of LXR activation on 
lipolysis and glucose uptake. Since LXRβ is expressed in most tissues and LXRα expression is 
restricted to a few tissues which are all lipid-metabolising, it is not entirely unexpected that 
LXRα is the major isoform involved in lipolysis and glucose uptake. LXRα has also previously 
been denoted the most important isoform in adipocyte metabolism [94, 95, 152].  
In paper II we shortly address an interesting aspect of cell biology. We show that primary 
pre-adipocytes from human subjects react in a BMI-specific manner to LXR stimulation, an 
observation that was repeated with the same outcome in mature ex vivo adipocytes. This 
implies that pre-adipocytes retain a metabolic memory even after two weeks of in vitro 
culturing. It also demonstrates the long-lasting effects of epigenetic imprinting and the 
importance of epigenetics in the future of individualised medicine, a topic not addressed in 
this thesis. Furthermore, we also made an interesting observation in the regulation of 
GLUT4 mRNA expression by LXR in different individuals. Since GLUT4 has been reported to 
be upregulated in human SGBS adipocyte-like cell line, it was surprising to observe that it 
remained unaltered in our primary cells. When performing a closer examination of the data, 
it emerged that GLUT4 was slightly downregulated in SVF-derived adipocytes from three of 
the subjects and slightly upregulated in the remaining three subjects – on average 
unchanged. This might imply that LXR-regulation of SLC2A4 varies between individuals and 
once again points to epigenetic mechanisms in the regulation of LXR-mediated transcription. 
To be mentioned, LXRα is more highly expressed than LXRβ in our human adipocyte cell 
systems (unpublished observation). In addition, LXRα is subject to positive autoregulation 
whereas LXRβ is not. Thus, when stimulating cells with an LXR agonist, LXRα expression is 
further increased. This difference in expression levels is important to have in mind since 
LXRα-specific effects may dominate when stimulating LXR activity. 
The main finding of paper I, that LXR upregulates lipolysis in adipocytes, is in line with 
studies in murine models. Increased basal lipolysis is a complication of obesity and the 
metabolic syndrome and could result in ectopic FA disposition on other organs, impairing 
their function. This implies that any drug trials investigating LXR as a pharmaceutical target 
must proceed with awareness of this potential side-effect. In addition, obese subjects have a 
much greater likelihood than lean to develop insulin resistance, and thus, the patients who 
would be considered for a possible treatment for type 2 diabetes with LXR-stimulating 
agents would be obese. Therefore, the finding that LXR downregulates glucose uptake only 
in adipocytes from obese subjects could be of clinical significance, and is the opposite of the 
desired outcome of such a treatment.  
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In paper III, we show that MAFB expression is increased in obese adipose tissue, and is 
enriched in macrophages, and that MAFB mediates inflammation in adipocytes.  
MAFB has been previously shown to regulate differentiation of a number of cell types. 
However, MAFB does not influence adipogenesis in human adipocytes in our study. On the 
other hand, its expression is strongly induced by adipocyte differentiation, indicating an 
important function in the mature adipocyte. As CEBPδ has been previously demonstrated to 
regulate MAFB in keratinocytes, it is possible that CEBPδ is mediating the upregulation of 
MAFB in adipocytes as well, which may be determined in future studies. 
Since MAFB expression is highly enriched in macrophages compared to adipocytes isolated 
from primary adipose tissue, and MAFB mRNA correlates strongly with macrophage markers 
within adipose tissue, we conclude that MAFB is a marker of macrophage abundance. Thus, 
elevated MAFB expression observed in adipose tissue from obese individuals likely come 
from increased macrophage content. Despite MAFB being downregulated in adipocytes, this 
downregulation does not likely affect total expression in adipose tissue to any large extent 
due to the massive MAFB expression originating from macrophages. 
The major role of MAFB in adipocytes appears to be as a mediator of inflammation. Its 
downregulation by TNFα in adipocytes could speculatively be interpreted as a negative 
feedback process, to stabilise the inflammatory response. Inflammation has a tendency to 
promote itself, and in order to prevent a vicious cycle of an ever amplified inflammatory 
response, such a feedback system might be necessary for the organism.  
In paper IV we show that SIK2 is differentially regulated by obesity in subcutaneous 
adipocytes and is a positive regulator of glucose uptake. To be noted, SIK2 expression was 
not altered by obesity in omental adipocytes from human subjects. This implies that SIK2 is 
either differentially regulated by weight gain in subcutaneous vs. omental fat, or that SIK2 
has different functions in these two depots. This would have to be determined further but a 
different regulation or role of SIK2 in omental fat is not unlikely considering recent research 
increasingly identifying differences between different fat depots.  
We also show that SIK2 is downregulated by TNFα. TNFα has been shown to suppress 
glucose uptake by a number of mechanisms discussed above, and our data indicate that 
inhibition of SIK2 expression might be added to the list. The specific mechanism of this 
suppression remains to be determined. A reduction in SIK2 protein expression is visible on 
western blot already after 3 h of TNFα treatment. This implies that SIK2 either has a short 
half-life and its expression is inhibited by TNFα, or that TNFα is stimulating SIK2 protein 
degradation.  
In our study, phosphorylation of HDAC4 and CRTC2 were diminished upon SIK inhibitor 
treatment. Although we can hypothesise that diminished phosphorylation of HDAC4 and 
CRTC2 might be involved in the suppression of glucose uptake, such a connection would 
have to be further investigated. However, SIK2 and HDAC4 have been previously implicated 
in the regulation of GLUT4 expression [125, 153] and a similar mechanism may be present in 
the cell system used in this study. When calculating the ratio of insulin-stimulated 
expression to basal in vehicle- and SIK inhibitor treated samples, it is unaltered. This implies 
that the insulin signalling cascade may not be involved in the SIK2-mediated regulation of 
glucose uptake. However, it does not automatically exclude a role of GLUT4, since a certain 
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amount of GLUT4 is present in the plasma membrane even in the unstimulated state, and 
may mediate basal glucose uptake alongside GLUT1. 
In unpublished data, SIK2 mRNA expression correlated positively with SLC2A4 mRNA. This 
implies that SIK2 either is associated with a favourable metabolic profile in general, or 
possibly is a positive regulator of GLUT4 expression. Moreover, SIK2 mRNA strongly and 
negatively correlated with adipocyte cell volume from humans with varying BMI. This is in 
line with recent findings where SIK2 knockout mice displayed increased adipocyte size [125]. 
A large adipocyte size is much more prominent in obesity and has been connected to 
dysregulated metabolism. Thus, as concluded based on data in paper IV, SIK2 seems to be 
associated with a healthy adipocyte phenotype.   
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6 EXTENDED DISCUSSION AND FUTURE PERSPECTIVES 
 
We use clinical cohorts to investigate correlations with clinical parameters and differential 
expression in obese/diabetic. This can provide clues on factors of importance in adipocyte 
biology, the development of obesity or its complications, and can often be the initiation 
point of a new investigation. All three factors studied in this thesis were found to be 
differentially expressed in obese adipose tissue compared to lean. In addition, having access 
to data from large clinical cohorts enriches studies as you can investigate the clinical 
relevance of your in vitro findings, place them in a context and strengthen your hypothesis. 
On the other hand, one must interpret statistical correlations with some degree of 
scepticism as correlation does not prove causation. In addition, one must be careful to 
statistically adjust for variables that might influence the association between two factors. In 
our cohorts, BMI and/or age, depending on the context, might serve as suitable variables to 
add into a regression analysis.  
NRs are compelling drug targets because of their function as binders of ligands, and the 
diversity of their effects. However, this diversity also poses a risk. Administering an 
exogenous molecule to an organism may indiscriminately and uncontrollably activate a 
receptor in all tissues simultaneously. A drug cannot be metabolised and controlled in the 
same way as the availability and abundance of endogenous ligands, which can be produced 
locally in certain tissues or be controlled in what way they are allowed to enter specific cell 
types. Schupp and Lazar [83] conclude that “some of the most effective therapeutic agents 
available today are derived from endogenous ligands of NRs, with the great example of anti-
inflammatory corticosteroids”. However, whereas corticosteroids are indeed highly effective 
in their suppression of inflammation, they also come with numerous side-effects, and tend 
to lose their power over time. 
LXR is an established regulator of cholesterol metabolism and a transrepressor of 
inflammatory genes. Therefore, it has been suggested as a pharmaceutical target. The role 
of LXR in other metabolic processes is somewhat controversial, and the findings of paper I 
and II add to the complexity. There seems to be important inter-species differences in LXR 
effects regarding glucose uptake, as concluded in paper II, where insulin signalling and 
glucose uptake is inhibited by LXR in human adipocytes. In addition, we show in paper I that 
stimulation of LXR in human adipocytes augments spontaneous lipolysis. Despite its 
beneficial effects on atherosclerosis and neurodegenerative diseases, activating LXR 
systemically may thus produce serious side-effects. In fact, the LXR agonist LXR-623 has 
been evaluated in a clinical phase one drug trial using healthy human subjects. The most 
common side-effects concerned the central nervous system, which was not the intended 
target tissue. The study did not report on glucose metabolism or lipolysis, but a brief 
mention on glucose levels stated that glucose levels did not exhibit abnormalities. 
An alternative approach to overcome negative effects of systemic NR activation is to 
investigate and take advantage of differential expression of NR subtypes, which opens up 
for tissue-specific drug development [154]. As the negative impacts on basal lipolysis and 
glucose transport has mainly been attributed to LXRα in paper I and II, isoform-specific 
targeting of LXRβ using a selective agonist might be a promising strategy to circumvent 
adverse metabolic side-effects in the treatment of e.g. neurodegenerative illness. Others 
suggest that targeting the co-factors of NRs might be an efficient approach [155]. 
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Indeed, an important aspect of LXR biology is the importance of co-factors. The 
discrepancies in LXR effects emerging when comparing data from different laboratories 
might depend on the relative expression levels of co-factors in the respective cell systems. In 
turn, these levels might depend on their origin, minor differences in differentiation 
protocols or other unknown factors. They might also fluctuate depending on experimental 
timing in mice, as many genes are known to be under the control of the circadian rhythm.  
In an attempt to summarise the physiological effects of LXR activation in the human context 
–considering that LXR stimulated spontaneous lipolysis and suppresses glucose uptake in 
adipocytes – one might speculate that stimulation of LXR mimics a situation where glucose 
and FAs are in demand for oxidation elsewhere, such as muscle. In line with this, it has been 
reported that LXR stimulates the uptake of both glucose and FA in human muscle cells [156, 
157]. In addition, the lipogenic genes FASN, SCD-1 and ACC1 were unaltered in our 
microarray profiling analysis, suggesting that lipogenesis was not stimulated by LXR agonist 
treatment. Our findings are further supported by the observation that LXR activation leads 
to smaller adipocytes [97] which goes in line with elevated FA release and decreased 
glucose uptake. 
In section 3.2, differences between animal models and human biology are discussed and a 
number of discrepancies between human and murine adipose tissue function are listed. The 
effect of LXR in glucose uptake adds to the list. In addition, the decreased SIK2 expression 
observed after weight loss in human adipocytes in paper IV, points to differential regulation 
between species in obesity as SIK2 has been shown to be upregulated in obese mice 
compared to wild-type [114]. This supports the use of human material in medical research 
in the initial investigations of a new factor. In the worst case scenario, a factor if importance 
for human health could in theory be dismissed as irrelevant based on initial findings in 
animal models. In other cases, huge amounts of research funding could be lost on studies in 
mice on a factor of little importance in human pathology. 
As mentioned earlier, macrophages are a necessary component of adipose tissue. Ablation 
of FA uptake by macrophages results in an unfavourable phenotype in mice [158]. This is 
also true for inflammation, which is likely needed for optimal function of the organism.  In 
support of this, mice deficient in the immune-response mediating CD40 receptor are insulin 
resistant [159]. However, excessive levels of inflammatory factors contribute to a chronic 
inflammatory state and metabolic disease. In this aspect, MAFB might very well contribute 
to the unfavourable phenotype of obesity. In support of this, MAFB correlates negatively 
with insulin sensitivity. However, the role of MAFB in metabolic dysregulation is still 
relatively unexplored, and needs adipocyte and/or in vivo models where MAFB expression is 
manipulated. Therefore, it is too soon to draw any conclusions about MAFB as a potential 
drug target or marker for metabolic disease. Future strategies in MAFB research could 
include identification of the distinct molecular mechanisms regulating MAFB in adipocytes 
and macrophages. 
SIKs share many characteristics and functions with the metabolic master switch AMPK. As 
AMPK, SIKs are phosphorylated and regulated by LKB1 and SIK2 is activated by increased 
AMP levels in 3T3-L1 adipocytes. However, this was not confirmed by other studies [160-
162]. Further, SIK substrates overlap with those of AMPK, and SIK2 phosphorylates the same 
site as AMPK on e.g. IRS [114, 163]. As AMPK, SIK2 appears important for metabolism. 
Although there is some controversy about the role of AMPK in adipocyte glucose uptake 
[164], AMPK was shown in one study to stimulate basal glucose uptake [165]. The same 
conclusion is drawn for SIK2 in paper IV. AMPK is activated by metformin, the most widely 
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used drug in type 2 diabetes treatment. Future research might determine if SIKs are of the 
same importance to human metabolism as AMPK and a potential drug target. Also, SIK2 
regulation by inflammation is intriguing and future studies might elucidate which pathway is 
mediating SIK2 downregulation by TNFα. Finally, SIK2 is relatively unexplored in adipose 
tissue and it would be of interest to further determine the mechanism by which SIK2 
inhibition suppresses glucose uptake. 
 
To conclude the findings of this thesis, we have shown that LXR, MAFB and SIK2 are 
regulators of human adipocyte metabolism and inflammation. We have found a deleterious 
role of LXR in the regulation of adipocyte lipolysis and glucose uptake. We further have 
identified the importance of MAFB and SIK in inflammation and metabolism, respectively – 
two proteins previously uninvestigated in human adipocytes. We show that MAFB and SIK2 
expression is altered in obesity and by TNFα treatment. In addition, MAFB it is required for 
mediating some of TNFα’s detrimental effects on adipocyte function. At last, we show that 
SIK2 is a positive regulator of glucose transport in human adipocytes. Together, these 
findings have contributed to the understanding of adipocyte function and could lead to the 
generation of interesting hypotheses and new projects. 
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